Europe Sees Uneven Care For Seizure-Linked Brain Tumors

What was studied

This study looked at how low-grade epilepsy-associated brain tumors (LEATs) are currently managed across Europe. LEATs are a frequent cause of drug-resistant focal epilepsy in both children and adults.

The researchers used a web-based survey from EpiCARE, a European network for rare and complex epilepsies. They collected answers from 172 clinicians working at 75 institutions in 26 European region countries. The survey asked about institutional protocols, individual practices, referral pathways, presurgical evaluation, histopathology, molecular diagnostics, and follow-up.

What they found

Many clinicians agreed that seizures are a major comorbidity in people with LEATs and that seizure frequency and seizure duration influence treatment decisions. Most supported early referral to an epilepsy surgery team after diagnosis, even without confirmed drug resistance. The abstract also notes that epilepsy surgery is a well-recognized treatment option, with almost 80% of patients seizure-free at 1 year, and about half of children seizure- and drug-free at 5 years.

At the same time, the survey found important differences in practice across Europe. Only 48% said their institution had protocols in place. About 66% said patients were systematically referred to an epilepsy team for presurgical assessment. A minority, 13%, said they required failure of at least two antiseizure medications. Most clinicians recommended follow-up beyond 1 year after surgery, and almost all said histopathology influenced follow-up decisions. Most were familiar with the 2021 WHO central nervous system tumor classification and molecular diagnostics.

Limits of the evidence

This was a survey of clinician opinions and reported practices, not a study of patient outcomes. It cannot show which approach is best or whether differences in practice are linked to seizure control, tumor outcomes, or quality of life.

The results may not represent every hospital or clinician in Europe, and answers may not fully match day-to-day care. The abstract does not give details about differences between children and adults, between tumor types, or between countries and centers.

For families and caregivers

For families, this suggests that many European specialists view these tumors not only as an oncological condition, but also as an epileptogenic lesion that can strongly affect quality of life. It also suggests that early review by an epilepsy surgery team is often considered, rather than always waiting for confirmed drug resistance.

But care is not fully standardized yet. Families may find that referral timing, testing before surgery, and use of molecular tests differ from one center to another. This study highlights the need for clearer guidelines so care is more consistent.

What to watch next

Future studies could look at how different referral and testing pathways relate to patient outcomes, and whether practices differ across age groups, tumor types, or centers.

Terms in this summary

LEAT

Low-grade epilepsy-associated brain tumor, a low-grade brain tumor associated with seizures.

focal epilepsy

Seizures that start in one area of the brain.

drug-resistant

Epilepsy that continues despite treatment with antiseizure medicines.

epilepsy surgery

Surgery used as a treatment option for epilepsy.

presurgical evaluation

Tests and specialist review done before surgery.

histopathology

Examination of tissue to identify tumor type and features.

molecular diagnostics

Tests that look at molecular features of a tumor.

multidisciplinary approach

Care planned by a team of different specialists working together.